الملخص
- Reactive process common to many malignant and benign disorders.
- Primary myelofibrosis is a chronic progressive disorder with a median lifespan (5.5 years) much shorter than that with other myeloproliferative disorders. However, survival can be heterogeneous, ranging from <1 year to >30 years.
- Leukoerythroblastosis and splenomegaly are common findings.
- Death is usually due to bone marrow failure (haemorrhage, anaemia, or infection), transformation to acute leukaemia, portal or pulmonary HTN, heart failure, cachexia, or myeloid metaplasia with organ failure.
- Asymptomatic, low-risk patients without hyperuricaemia or a remedial cause for anaemia require no therapy.
- Haematopoietic stem cell transplant is the only treatment option with a potential for cure.
Other related conditions
- Polycythaemia vera
- Essential thrombocytosis
- Chronic myelogenous leukaemia
- Myelodysplastic syndrome
- Acute myelogenous leukaemia
- Acute lymphocytic leukaemia
- Hairy cell leukaemia
- Hodgkin's lymphoma
- Non-Hodgkin's lymphoma
- Multiple myeloma
- Primary hyperparathyroidism
- Vitamin D deficiency
- Systemic lupus erythematosus
- Overview of HIV
- Pulmonary tuberculosis
- Assessment of pancytopenia
- Assessment of thrombocytopenia
- Assessment of anaemia
- Assessment of splenomegaly
- Overview of leukaemia
- Nephrolithiasis
- Gout
:آخر تحديث ينا 14, 2013
